Kura Oncology Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating Activities | |||
| Net loss | $(152,631) | $(135,840) | $(130,466) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Share-based compensation expense | 28,082 | 26,318 | 23,579 |
| Amortization of premium and accretion of discounts on marketable securities, net | (9,420) | 1,610 | 4,391 |
| Depreciation expense | 849 | 759 | 558 |
| Non-cash interest expense | 477 | 73 | 399 |
| Loss from extinguishment of debt | — | — | 212 |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (1,960) | (2,935) | (357) |
| Operating lease right-of-use and other long-term assets | (685) | 571 | (329) |
| Accounts payable and accrued expenses | 10,327 | (802) | (2,518) |
| Other long-term liabilities | 137 | 184 | (20) |
| Net cash used in operating activities | (124,824) | (110,062) | (104,551) |
| Investing Activities | |||
| Maturities of marketable securities | 425,549 | 303,908 | 319,969 |
| Purchases of marketable securities | (409,824) | (270,655) | (445,657) |
| Purchases of property and equipment | (168) | (626) | (1,147) |
| Net cash provided by (used in) investing activities | 15,557 | 32,627 | (126,835) |
| Financing Activities | |||
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | 93,577 | 24,721 | — |
| Proceeds from issuance of stock under equity plans | 1,206 | 4,419 | 4,426 |
| Proceeds from long-term debt | — | 10,000 | — |
| Payment of fees related to issuance of long-term debt | — | (575) | — |
| Repayment of long-term debt | — | — | (7,250) |
| Payment of fees related to extinguishment of debt | — | — | (611) |
| Net cash provided by (used in) financing activities | 94,783 | 38,565 | (3,435) |
| Net decrease in cash, cash equivalents | (14,484) | (38,870) | (234,821) |
| Cash and cash equivalents at beginning of period | 51,802 | 90,672 | 325,493 |
| Cash and cash equivalents at end of period | $37,318 | $51,802 | $90,672 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid | $1,064 | $73 | $784 |
| Supplemental non-cash disclosures: | |||
| Warrants issued in connection with debt facility | $— | $294 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.